Body Pharm Ipamorelin 5

The Body Pharm Ipamorelin 5 mg vial is a selective growth-hormone secretagogue research peptide, supplied through JCSG.org to United Arab Emirates laboratories as a sterile lyophilised powder for reconstitution. It is intended exclusively for in vitro and preclinical research use — not for human or veterinary use. Live AED pricing is shown in the buy box on this product page.

Key takeaways

• Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that triggers pulsatile growth-hormone release without measurable cortisol, ACTH or prolactin elevation.
• The selectivity profile derives from the D-2-naphthylalanine substitution in the pentapeptide backbone, first documented by Raun et al. 1998 and confirmed by Johansen et al. 1999.
• Body Pharm ipamorelin 5 mg is supplied as a lyophilised powder with a batch-specific Certificate of Analysis; current AED pricing should be verified at checkout.
• Standard research panels pair ipamorelin with CJC-1295 to combine pulsatile ghrelin-receptor stimulation with tonic GHRH amplification.
• Peptide classification and free-zone compliance should be confirmed with your institutional compliance officer before ordering.

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide GHS-R1a agonist with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 and a molecular weight of 711.85 g/mol (PubChem CID 9831659). It mimics endogenous ghrelin at the pituitary somatotroph, triggering pulsatile growth-hormone release without measurable elevation of ACTH, cortisol or prolactin at effective doses.

Unlike tesamorelin, a stabilised GHRH(1-44) analogue acting on the GHRH receptor, ipamorelin is a ghrelin-mimetic. The two pathways are complementary rather than redundant: GHRH agonists amplify somatotroph GH synthesis, while GHS-R1a agonists like ipamorelin trigger release. That distinction is the pharmacological rationale for co-administration protocols pairing ipamorelin with CJC-1295, where the two peptides converge on somatotroph activation through separate receptor systems.

Mechanism at a glance

GHS-R1a is a Gq-coupled receptor expressed on anterior pituitary somatotrophs and on hypothalamic arcuate neurons. Ipamorelin binding initiates phospholipase C activation, IP3-mediated calcium mobilisation and exocytosis of pre-formed GH vesicles. The result is a sharp, short-duration pulsatile GH release rather than tonic elevation. Reported pharmacodynamics in practitioner syntheses describe a Tmax at 15–30 minutes post-subcutaneous administration, a circulating half-life near two hours, and a GH pulse duration of two to three hours.

Raun et al. 1998 (European Journal of Endocrinology) established that ipamorelin matches earlier growth-hormone-releasing peptides for GH-releasing potency while sparing the HPA axis and lactotrophs. That receptor selectivity is the most-cited reason researchers choose ipamorelin over earlier GHRPs for endocrine study designs requiring isolated GH-axis stimulation.

Selectivity: GH, cortisol, prolactin and ACTH

Ipamorelin is the first-generation growth-hormone-releasing peptide that triggers a significant GH pulse without measurable elevation of cortisol, ACTH or prolactin in the original preclinical work. This dissociation is why researchers designing isolated GH-axis stimulation studies select ipamorelin over GHRP-6 or GHRP-2, both of which co-stimulate the HPA axis at GH-equivalent doses.

The structural basis is the D-2-naphthylalanine (D-2-Nal) substitution at position 2 of the pentapeptide backbone. This substitution preserves GHS-R1a affinity while reducing engagement of receptor populations linked to corticotroph and lactotroph release. Raun et al. 1998 demonstrated GH-releasing potency comparable to reference compounds in swine and rat models without the cortisol or ACTH spikes characteristic of those compounds. Johansen et al. 1999 (Growth Hormone & IGF Research) extended this with prolactin data showing no significant lactotroph activation at doses producing maximal GH release. This selectivity advantage is documented in preclinical models; no recent human head-to-head trial has replicated the full profile, so researchers should treat the selectivity margin as directionally reliable but quantitatively unverified.

What researchers study

Ipamorelin-induced GH pulses drive hepatic IGF-1 transcription via the JAK2/STAT5 pathway, making serum IGF-1 the standard downstream endpoint in sustained-dosing preclinical work. Acute single-dose studies typically capture only the GH pulse itself (Tmax 15–30 minutes subcutaneously, pulse duration two to three hours). IGF-1 elevation requires repeated administration across days to weeks before hepatic output stabilises at a new setpoint.

GHS-R1a is densely expressed in the arcuate and ventromedial hypothalamic nuclei and on pituitary somatotrophs, with lower-density expression in hippocampus, pancreatic islets and myocardium. For researchers running central versus peripheral readouts, this distribution matters: hypothalamic GHRH neurons and direct somatotroph stimulation both contribute to the observed GH pulse, and selective antagonist pre-treatment is the cleanest way to dissect the two contributions in animal models.

For study designs modelling endogenous ghrelin signalling or examining acute GH pulse kinetics without confounding cortisol or prolactin variance, ipamorelin is the cleaner tool. For protocols requiring sustained activation of the GHRH receptor — visceral-adiposity or IGF-1 trajectory models — tesamorelin is the appropriate comparator. For long-interval designs where weekly administration matches the experimental window, CJC-1295 supplies multi-day GHRH-receptor occupancy via albumin binding.

Body Pharm ipamorelin 5 mg: specifications

The Body Pharm ipamorelin 5 mg vial is supplied as a sterile lyophilised powder for reconstitution, intended exclusively for in vitro and preclinical research use. Each vial contains 5 mg of pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), sealed under inert atmosphere with a butyl rubber stopper and aluminium crimp. Request the batch-specific Certificate of Analysis at the time of order to confirm peptide content, water content and residual TFA for the lot received.

The 2026 expectation for reputable ipamorelin suppliers is at least 98% HPLC purity, with 99% increasingly treated as the benchmark. Mass-spectrometry identity confirmation, endotoxin testing and residual-TFA quantification should appear on the batch CoA. Exact lot purity should be verified against the CoA supplied with the shipment rather than assumed from the product page.

Parameter	Value
Peptide identity	Ipamorelin, Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular weight	711.85 g/mol
Format	5 mg lyophilised powder vial
Purity benchmark	at least 98% HPLC (verify on batch CoA)
Storage (unopened)	−20 °C, protected from light and moisture

How to reconstitute ipamorelin for research

Ipamorelin is reconstituted by dissolving the lyophilised powder in bacteriostatic water or sterile PBS at a typical research stock concentration around 1 mg/mL, then aliquoted and stored cold to avoid freeze-thaw degradation. The peptide is soluble in aqueous buffers at standard research concentrations and does not require organic co-solvents for routine in vitro work.

1. Calculate the target concentration for the downstream assay (for example, a 1 mg/mL stock from a 5 mg vial requires 5 mL of diluent; a 2 mg/mL stock requires 2.5 mL).
2. Select the diluent: bacteriostatic water (0.9% benzyl alcohol) for multi-day use, or sterile PBS for single-session assays where preservative interference is undesirable.
3. Inject the diluent slowly down the inner wall of the vial using a sterile syringe. Do not direct the stream onto the lyophilisate cake and do not vortex.
4. Swirl gently at room temperature until the solution is clear. Full dissolution typically occurs within one to two minutes.
5. Aliquot into single-use volumes (for example, 100 microlitres in low-bind tubes) to eliminate repeat freeze-thaw cycles.
6. Store working aliquots at 4 °C for up to seven days, or at −20 °C for longer-term storage.
7. Label each aliquot with peptide ID, concentration, diluent, reconstitution date and operator initials, and log the lot number and CoA reference in the institutional reagent register.

Bacteriostatic water, sterile syringes and low-bind aliquot tubes should be ordered alongside the vial to avoid delays at reconstitution.

Regulatory and compliance context in the UAE

Ipamorelin supplied through JCSG.org is for in vitro and preclinical research use only and is not intended for human or veterinary administration. Every vial should be treated as a laboratory reagent destined for a controlled research environment, with handling, storage and disposal logged against the receiving institution's standard operating procedures.

Peptide importation and domestic distribution in the UAE fall under the relevant national health-authority oversight, which regulates pharmaceuticals and related substances under category-level frameworks rather than a peptide-specific schedule. Free-zone or research-use labelling does not exempt an entity from that oversight or from customs review. Standard documentation requested at the border typically includes the commercial invoice, packing list, Certificate of Analysis and safety data sheet. This is not legal advice; verify all obligations with your institutional compliance officer before raising a purchase order.

Related GH-axis peptides in the UAE range

Ipamorelin is most useful when characterised against the broader GH-axis panel a researcher can source from a single supplier. The standard pairing combines CJC-1295 as the tonic GHRH drive with ipamorelin as the pulsatile ghrelin-receptor stimulus. For sustained GHRH-axis and visceral-adiposity models, tesamorelin is the comparator arm. A single procurement file can cover a full mechanistic GH-axis study, and the same supplier stocks tissue-repair tools BPC-157 and TB500 for researchers extending their work.

Frequently asked questions